Par Historical Cash Flow

PAR Stock   290.40  11.35  4.07%   
Analysis of Par Drugs cash flow over time is an excellent tool to project Par Drugs And future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 33.2 M or Other Non Cash Items of 3.2 M as it is a great indicator of Par Drugs ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Par Drugs And latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Par Drugs And is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Par Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Par balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Par's non-liquid assets can be easily converted into cash.

Par Drugs Cash Flow Chart

At present, Par Drugs' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Change In Working Capital is expected to grow to about 21 M, whereas Other Cashflows From Financing Activities is projected to grow to (55.5 M).

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.

Capital Expenditures

Capital Expenditures are funds used by Par Drugs And to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Par Drugs operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Par Drugs And financial statement analysis. It represents the amount of money remaining after all of Par Drugs And operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Par Drugs' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At present, Par Drugs' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Change In Working Capital is expected to grow to about 21 M, whereas Other Cashflows From Financing Activities is projected to grow to (55.5 M).
 2021 2023 2024 (projected)
Capital Expenditures32.0M60.8M32.4M
Dividends Paid15.4M17.7M18.6M

Par Drugs cash flow statement Correlations

0.590.450.510.47-0.340.40.210.40.480.28-0.3-0.25-0.19-0.370.43-0.45
0.590.610.590.39-0.420.620.580.590.810.51-0.51-0.04-0.21-0.670.58-0.65
0.450.610.70.320.00.390.580.330.540.4-0.39-0.19-0.27-0.250.37-0.26
0.510.590.7-0.020.20.140.8-0.030.30.05-0.190.03-0.07-0.020.050.04
0.470.390.32-0.02-0.590.70.180.750.760.84-0.81-0.69-0.71-0.50.85-0.64
-0.34-0.420.00.2-0.59-0.830.17-0.92-0.61-0.580.530.250.520.89-0.710.84
0.40.620.390.140.7-0.830.240.950.820.77-0.82-0.35-0.47-0.760.81-0.83
0.210.580.580.80.180.170.240.040.390.2-0.390.04-0.17-0.010.10.08
0.40.590.33-0.030.75-0.920.950.040.830.81-0.74-0.37-0.56-0.880.87-0.91
0.480.810.540.30.76-0.610.820.390.830.92-0.85-0.41-0.5-0.720.91-0.84
0.280.510.40.050.84-0.580.770.20.810.92-0.89-0.57-0.57-0.590.93-0.78
-0.3-0.51-0.39-0.19-0.810.53-0.82-0.39-0.74-0.85-0.890.670.550.44-0.880.69
-0.25-0.04-0.190.03-0.690.25-0.350.04-0.37-0.41-0.570.670.660.1-0.70.42
-0.19-0.21-0.27-0.07-0.710.52-0.47-0.17-0.56-0.5-0.570.550.660.51-0.640.41
-0.37-0.67-0.25-0.02-0.50.89-0.76-0.01-0.88-0.72-0.590.440.10.51-0.690.85
0.430.580.370.050.85-0.710.810.10.870.910.93-0.88-0.7-0.64-0.69-0.9
-0.45-0.65-0.260.04-0.640.84-0.830.08-0.91-0.84-0.780.690.420.410.85-0.9
Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory13.8M(799.1K)(17.2M)(6.7M)12.0M12.6M
Change In Cash73.5M137.8M(49.6M)60.4M144.1M151.3M
Free Cash Flow61.3M70.4M44.1M57.4M141.7M76.0M
Change In Working Capital(8.5M)(3.4M)(54.3M)(4.6M)20.0M21.0M
Other Cashflows From Financing Activities(1.6M)26.5M(3.8M)(24K)(58.4M)(55.5M)
Depreciation27.6M28.2M32.8M32.3M34.4M33.2M
Other Non Cash Items(2.1M)(51.2M)(29.4M)(44.7M)3.1M3.2M
Capital Expenditures15.6M50.5M32.0M76.3M60.8M32.4M
Total Cash From Operating Activities76.9M120.9M76.2M133.8M202.5M108.3M
Change To Account Receivables(38.5M)(831K)(60.2M)15.0M32.4M34.0M
Net Income59.9M147.3M127.0M150.8M145.0M88.5M
Total Cash From Financing Activities11.1M16.5M(95.5M)(24K)(27.6K)(29.0K)
End Period Cash Flow73.8M211.6M162.1M222.4M366.5M384.9M
Begin Period Cash Flow305.9K73.8M211.6M162.1M222.4M233.6M
Net Borrowings(73.3M)(57.3M)30.2M(76.4M)(68.8M)(65.3M)
Total Cashflows From Investing Activities(2.5M)(14.6M)507.1K(30.2M)(27.2M)(25.8M)
Change To Operating Activities(31.8M)3.4M(6.9M)(16.4M)(14.7M)(15.5M)
Other Cashflows From Investing Activities887.0K764.8K1.3M1.8M2.1M1.1M
Change To Netincome13.5M10.2M(20.1M)5.4M4.9M5.6M
Change To Liabilities(3.3M)12.7M5.1M39.4M45.4M47.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

The Cash Flow Statement is a financial statement that shows how changes in Par balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Par's non-liquid assets can be easily converted into cash.